Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 13/20 | 0.40 |
| ▸ | HTR2B | P41595 | 13/20 | 0.40 |
| ▸ | HTR2A | P28223 | 9/20 | 0.40 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.37 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2650583 | 0.76 | HTR2C (0.41) | HTR2CHTR2BHTR2AADRB1 | |
| SCHEMBL1923622 | 0.73 | HTR2C (0.40) | HTR2CHTR2BHTR2AADRB1 | |
| SCHEMBL8730096 | 0.70 | SLC6A4 (0.55) | KMT2A | |
| SCHEMBL6128340 | 0.67 | CHRNB2 (0.44) | ALDH1A1GAAMAPTHTTSMN1; SMN2 | |
| SCHEMBL4574778 | 0.66 | DPP4 (0.34) | — | |
| SCHEMBL6015072 | 0.64 | HTR2C (0.43) | HTR2CHTR2BHTR2AADRB1 | |
| SCHEMBL18284815 | 0.64 | TAAR1 (0.44) | HTR2CHTR2BHTR2A | |
| SCHEMBL15830018 | 0.63 | PRMT5 (0.46) | ALDH1A1 | |
| SCHEMBL15824978 | 0.63 | TAAR1 (0.43) | HTR2CHTR2BHTR2A | |
| SCHEMBL11006977 | 0.63 | POLB (0.35) | HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2586774-A1 | METHOD FOR PREPARATION OF RANOLAZINE | Shanghai Kuoikee Laboratories Co., Ltd (CN) | 2013-05-01 | — | — | EP | claimed |
| US-20130090475-A1 | Process for the Preparation of Ranolazine | ZHEJIANG JIANFENG HAIZHOU PHARMACEUTICAL CO., LTD. (CN) | 2013-04-11 | — | — | US | claimed |
| EP-2586774-A1 | METHOD FOR PREPARATION OF RANOLAZINE | Shanghai Kuoikee Laboratories Co., Ltd (CN) | 2013-05-01 | — | — | EP | disclosed |
| US-20130090475-A1 | Process for the Preparation of Ranolazine | ZHEJIANG JIANFENG HAIZHOU PHARMACEUTICAL CO., LTD. (CN) | 2013-04-11 | — | — | US | disclosed |
| WO-2011160396-A1 | METHOD FOR PREPARATION OF RANOLAZINE | 上海冠杰生物医药科技有限公司 (CN) | 2011-12-29 | — | — | WO | disclosed |
| EP-1339701-B1 | HETEROARYL ALKYL PIPERAZINE DERIVATIVES AS FATTY ACID OXIDATION INHIBITORS | CV THERAPEUTICS INC (US) | 2007-02-14 | — | — | EP | disclosed |
| US-6849632-B2 | Heteroaryl alkyl piperazine derivatives | CV THERAPEUTICS, INC. (US) | 2005-02-01 | — | — | US | disclosed |
| US-20040192702-A1 | Heteroaryl alkyl piperazine derivatives | ZABLOCKI JEFF (US) | 2004-09-30 | — | — | US | disclosed |
| US-20040029889-A1 | Heteroaryl alkyl piperazine derivatives as fatty acid oxidation inhibitors | CV THERAPEUTICS, INC. | 2004-02-12 | — | — | US | disclosed |
| US-20030216409-A1 | Heteroaryl alkyl piperazine derivatives | CV THERAPEUTICS, INC. | 2003-11-20 | — | — | US | disclosed |
| EP-1339701-A1 | HETEROARYL ALKYL PIPERAZINE DERIVATIVES AS FATTY ACID OXIDATION INHIBITORS | CV THERAPEUTICS, INC. (US) | 2003-09-03 | — | — | EP | disclosed |
| US-6573264-B1 | Protecting skeletal muscles against damage, treating shock conditions, preserving donor tissue and organs used in transplants, treating cardiovascular diseases | CV THERAPEUTICS, INC. | 2003-06-03 | — | — | US | disclosed |
| WO-2002064576-A1 | HETEROARYL ALKYL PIPERAZINE DERIVATIVES AS FATTY ACID OXIDATION INHIBITORS | CV THERAPEUTICS, INC. (US) | 2002-08-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040029889-A1 | Heteroaryl alkyl piperazine derivatives as fatty acid oxidation inhibitors | CPT1B, CPT1A, ALOX15 | HTR2C 3752/4885HTR2B 3873/4885HTR2A 3260/4885 |
| US-20040192702-A1 | Heteroaryl alkyl piperazine derivatives | ATP2A1, CPT1B, ATP2A3 | HTR2C 4175/4885HTR2B 4364/4885HTR2A 3772/4885 |
| US-20030216409-A1 | Heteroaryl alkyl piperazine derivatives | ATP2A1, CPT1B, ATP2A3 | HTR2C 4175/4885HTR2B 4364/4885HTR2A 3772/4885 |
| US-20130090475-A1 | Process for the Preparation of Ranolazine | RANBP1, RANBP2, RAN | HTR2C 1246/4885HTR2B 2278/4885HTR2A 1309/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.